LONDON, Feb 2 (Reuters) - The COVID-19 vaccine developed by
Oxford University and AstraZeneca has 76% efficacy against
symptomatic infection for three months after a single dose, with
efficacy improving when a second shot is given later, a preprint
study showed on Tuesday.
Oxford University said the findings supported a decision
made by Britain to extend the interval between initial doses and
booster doses of the shot to 12 weeks.
(Reporting by Alistair Smout
Editing by Gareth Jones)